These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22298106)

  • 1. What are new avenues for renal protection, in addition to RAAS inhibition?
    Hagiwara S; Kantharidis P; Cooper ME
    Curr Hypertens Rep; 2012 Apr; 14(2):100-10. PubMed ID: 22298106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers: RAAS blockade and renoprotection.
    Ruilope LM
    Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL; Madias NE
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
    Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and old agents in the management of diabetic nephropathy.
    Lytvyn Y; Bjornstad P; Pun N; Cherney DZ
    Curr Opin Nephrol Hypertens; 2016 May; 25(3):232-9. PubMed ID: 26890303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
    Brenner BM; Zagrobelny J
    Kidney Int Suppl; 2003 Feb; (83):S77-85. PubMed ID: 12864880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.